Basis for BioVie's Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer's Disease Published in Neurodegenerative Disease ManagementGlobeNewsWire • 07/16/21
Development of BioVie's NE3107 Asset Featured by the American Diabetes AssociationGlobeNewsWire • 06/29/21
BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®GlobeNewsWire • 06/25/21
BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedixGlobeNewsWire • 05/10/21
